Head-To-Head Analysis: Imprimis Pharmaceuticals (IMMY) and Its Peers

Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Imprimis Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Imprimis Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -1.96
Imprimis Pharmaceuticals Competitors $290.27 million $35.99 million 52.54

Imprimis Pharmaceuticals’ peers have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Imprimis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -6,408.50% -83.97% -35.60%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Imprimis Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 956 3406 11909 239 2.69

Imprimis Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 177.78%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.74%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Imprimis Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

12.6% of Imprimis Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Imprimis Pharmaceuticals has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ peers have a beta of 2.51, suggesting that their average share price is 151% more volatile than the S&P 500.


Imprimis Pharmaceuticals peers beat Imprimis Pharmaceuticals on 9 of the 13 factors compared.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply